Confronto tra tofacitinib e ustekinumab come terapia di terza linea nella colite ulcerosa

Introduction Ulcerative colitis (UC) is a chronic inflammatory bowel disease that affects millions of people worldwide. While several medical therapies are available for the treatment of UC, Despite the development of several new medical therapies in the past years, it remains difficult to induce remission and prevent the need for surgery in patients with Ulcerative colitis. Study Objective The objective of this study is to examine the outcomes of treatment with tofacitinib and ustekinumab as a third-line therapy in refractory ulcerative colitis. Methods We conducted a retrospective study of 36 patients diagnosed with UC who received tofacitinib and ustekinumab as third-line therapies for refractory UC. Data was collected from patient medical records and included demographic information, medical history, laboratory test results, and clinical scoring systems such as the partial Mayo score, rectal bleeding score, stool frequency score, and fecal calprotectin levels. We used SPSS version 26 statistical software to analyze the data. Descriptive statistics, including means, standard deviations, and percentages, were calculated for each variable. Differences between the tofacitinib and ustekinumab groups were evaluated using independent sample t-tests for continuous variables and chi-square tests for categorical variables. A p-value of less than 0.05 was considered statistically significant. Results Rectal Bleeding has improved in both groups of patients. patients in the group receiving Ustekinumab had a better condition in terms of Rectal Bleeding score. Stool Frequency improved in the patients of both groups, but the group receiving Ustekinumab had a better condition in terms of Stool Frequency score. Partial Mayo Score had improved in the patients of both groups. the condition in terms of Partial Mayo Score was the same in both groups. the status of Fecal Calprotectin showed that it improved in both groups, but this situation improved more in patients receiving Tofacitinib. CRP decreased in both groups, but this decrease was more in the group receiving Ustekinumab. both drugs used had an acceptable effect on the improvement of patients. Conclusion In general, the results of this study showed that neither Ustekinumab nor Tofacitinib is preferable to each other and both drugs are effective in patients.

confronto tra tofacitinib e ustekinumab come terapia di terza linea nella colite ulcerosa